Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Cancer Cell(2021)10.1016/j.ccell.2021.07.023Source: DataRank Database

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy is a research paper published in Cancer Cell (2021). On theSindex it has a DataRank of 3.9. It has been cited 135 times, with 100 citing works in its 1-hop citation network.

N/A

3.9DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access135 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

geo gen uniprot nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02196181

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (27 grants)Impact (FWCI 8.35)OA: hybridTopics (40)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 19%Citation Network 81%

Base Score Contribution

0.737

From this paper's citation signal

Citation Network Contribution

3.2

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Melanoma: Does Sequencing Really Matter?
Journal of Clinical Oncology20228 citations11 referencesContributes 0.200
The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors
Scientific Reports202222 citations25 referencesContributes 0.125
Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
OncoImmunology202115 citations25 referencesContributes 0.111
Tumor-derived exosomes deliver the tumor suppressor miR-3591-3p to induce M2 macrophage polarization and promote glioma progression
Oncogene2022122 citations50 referencesContributes 0.096
Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients
Frontiers in Oncology202213 citations35 referencesContributes 0.075

Authors (21)

Sixue Liu ORCID,Zhentao Yang ORCID,Alain P. Algazi ORCID,Shirley H. Lomeli ORCID,Yan Wang ORCID

Live enrichment

PubMed:34416167 PMC:PMC9126729 OpenAlex:https://openalex.org/W3195642548

National Institute of General Medical Sciences

Grant: P20GM121293

Jonsson Comprehensive Cancer Center

Grant: T32CA009120

Parker Institute for Cancer Immunotherapy

Grant: R35 CA197633

National Institutes of Health

Grant: 1P01CA168585

National Institutes of Health

Grant: 1R01CA176111A1

National Institutes of Health

Grant: 1R21CA215910-01

National Institutes of Health

Grant: R21CA255837-01

University of California, Los Angeles

Grant: P30 CA016042

NCI NIH HHS

Grant: P01 CA168585

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: P01 CA244118

NCI NIH HHS

Grant: R01 CA176111

NCI NIH HHS

Grant: U10 CA180819

NCI NIH HHS

Grant: U10 CA180888

NCI NIH HHS

Grant: R21 CA215910

NCI NIH HHS

Grant: R21 CA255837

Bristol-Myers Squibb

Melanoma Research Alliance

Stand Up To Cancer

Daiichi-Sankyo

Sanofi

Novartis

AstraZeneca

Roche

V Foundation for Cancer Research

Merck

Pfizer

FWCI

8.35

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttp://www.cell.com/article/S1535610821004025/pdf

publisherhttp://www.cell.com/article/S1535610821004025/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1535610821004025?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610821004025?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2021.07.023

Fields of Study

Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses

MeSH Terms

Immune Checkpoint InhibitorsAnimalsHumansImmunotherapyNeoplasmsMitogen-Activated Protein Kinase KinasesMice

Keywords

Cancer researchMelanomaNeuroblastoma RAS viral oncogene homologMAPK/ERK pathwayTrametinibCytotoxic T cellImmunotherapyDabrafenibImmune checkpointImmune systemMedicineCD8ImmunologyTargeted therapyBiologyVemurafenibColorectal cancerMetastatic melanomaKinaseCancerInternal medicineBrain metastasisColorectal CarcinomaPancreatic Ductal AdenocarcinomaTumor Immune MicroenvironmentAnti-ctla-4Braf/nras/kras/nf1Mapk/braf/mek Inhibitor ResistanceAnti-pd-1/l1Sequential-combination Therapy

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Exploring immunotherapy in colorectal cancer

10.6084/m9.figshare.20330034.v1figshare

Additional file 1 of Exploring immunotherapy in colorectal cancer

10.6084/m9.figshare.20330034figshare